Most people can name the condition behind their high blood pressure or rising blood sugar. Fewer can name what happens when those two problems – plus excess weight, abnormal cholesterol, and reduced kidney function – all show up together and start feeding each other. That combination has a name, and the vast majority of Americans have never heard it.
The condition is called cardiovascular-kidney-metabolic syndrome, or CKM syndrome, and it was only formally defined three years ago. CKM syndrome, defined by the American Heart Association in 2023, describes the interconnected risks of metabolic dysfunction, chronic kidney disease, and cardiovascular disease. Those aren’t three separate problems sitting side by side. They’re part of a self-reinforcing cycle: each condition accelerates the others, driving damage to the heart, the kidneys, and the body’s ability to regulate blood sugar, often simultaneously.
What makes this particularly striking is how quietly it can build. Metabolic syndrome symptoms – the early-stage signals of high blood sugar, excess belly fat, elevated blood pressure, and abnormal lipids – rarely feel alarming on their own. But each one nudges the body closer to a far more serious set of consequences. And the numbers suggest most Americans are already somewhere on that spectrum, whether they know it or not.
The 90% Statistic That Should Be Impossible to Ignore
Cardiovascular-kidney-metabolic syndrome affects approximately 90% of U.S. adults, arising from the convergence of metabolic dysfunction, chronic kidney disease, and cardiovascular disease. An AHA newsroom announcement from 2025 confirmed that about 9 in 10 U.S. adults have never heard of it. That means almost the same share of the population is at risk as has never encountered the term.
To understand why the numbers are so high, look at the individual risk factors that feed CKM syndrome. High blood pressure, high fasting blood glucose, high fasting triglycerides, and low HDL (good) cholesterol levels – the classic markers of metabolic dysfunction – each raise the risk of cardiovascular disease and type 2 diabetes. In the U.S., these conditions are anything but rare. Global metabolic syndrome prevalence rose from 14.7% among women and 9.0% among men in 2000, to 31.0% among women and 25.7% among men by 2023, according to a 2025 systematic review published in Nature Communications covering 45.5 million adults across 198 countries.
The U.S. picture is even more concentrated. Metabolic syndrome is characterized by a cluster of conditions including abdominal obesity, high blood pressure, and abnormal blood sugar and lipid levels. Each of those factors is now extraordinarily common. Abdominal obesity, insulin resistance, abnormal lipids, elevated blood glucose, and high blood pressure are the core metabolic syndrome criteria – each a recognized cardiovascular risk factor in its own right. Currently, an estimated 1.54 billion adults globally had metabolic syndrome in 2023, making it one of the largest drivers of preventable chronic disease worldwide.
In the U.S. specifically, the numbers behind each individual risk factor are staggering. Obesity prevalence in the U.S. now stands at 40.3% of adults, according to CDC data. Nearly half of U.S. adults have high blood pressure. High blood pressure alone was a primary or contributing cause of 680,179 deaths in the United States in 2024, according to CDC statistics. On the diabetes and prediabetes front, 40.1 million Americans have diagnosed or undiagnosed diabetes – representing 12% of the population – and 115.2 million American adults, more than 2 in 5, have prediabetes, based on CDC research data. Kidney disease adds another layer: chronic kidney disease affects more than 1 in 7 U.S. adults, an estimated 35.5 million Americans, according to the National Institute of Diabetes and Digestive and Kidney Diseases.
Add those populations together and it becomes clear why so many people qualify for at least one CKM risk factor – often without knowing their kidneys, blood pressure, and metabolic health are already working against each other.
What the Stages Actually Mean for You
The American Heart Association’s 2023 staging framework stratifies CKM from Stage 0 – no risk factors – through Stage 4, which represents clinical cardiovascular disease with persistent metabolic dysfunction. Most people don’t fall at the extremes. Population-based studies reveal that Stage 2, defined by the presence of metabolic risk factors or early chronic kidney disease, represents the most prevalent category – affecting nearly half of adults in Western cohorts.
Each stage matters because each carries a different risk trajectory. Progression occurs in 34% of Stage 1 individuals, with each stage transition conferring an incrementally higher cardiovascular mortality risk. The implication is that the staging system isn’t just a label – it’s a tool for timing intervention before the biological cascade becomes harder to interrupt.
Stage 1 is defined by excess or dysfunctional body fat and/or elevated blood glucose or prediabetes, without other metabolic complications. Stage 2 introduces more serious metabolic risk factors – high triglycerides, hypertension, full metabolic syndrome, or type 2 diabetes – alongside moderate-to-high-risk chronic kidney disease, while Stage 3 moves into subclinical cardiovascular disease. The CKM staging system is designed to provide ongoing opportunities for screening and interventions to slow, halt, or reverse disease progression before heart failure or kidney failure sets in.
For people in the middle stages, the conditions reinforce each other through a specific biological sequence. CKM syndrome is rooted in shared mechanisms: chronic inflammation, insulin resistance (the body’s inability to respond normally to insulin), endothelial dysfunction (damage to the inner lining of blood vessels), and adverse vascular remodeling. Dysfunctional body fat drives insulin resistance, which impairs kidney filtration, which accelerates cardiovascular strain – and each of those in turn makes the others worse. The body doesn’t experience these as three separate problems. It experiences them as one.
For more on how cardiometabolic conditions interact and compound over time, this piece on heart disease and cancer risk covers the biological overlap that makes CKM syndrome relevant well beyond cardiovascular health alone.
Why America Lands Here
The ordinary pressures of daily life in the U.S. go a long way toward explaining why CKM syndrome is so widespread. In 2025, the European Atherosclerosis Society also reconceptualized traditional metabolic syndrome as a “systematic metabolic disorder” – acknowledging a cluster of metabolic abnormalities affecting multiple organs, leading to increased morbidity and mortality from both cardiovascular and non-cardiovascular causes. The renaming reflects a broader recognition that lifestyle-driven metabolic risk is not a personal failing – it’s a structural consequence of how modern societies are built.
Sedentary work, sleep pressure, processed-food availability, and financial stress all independently worsen the underlying components of CKM syndrome. The syndrome stems mainly from an energy imbalance caused by unhealthy diets and sedentary lifestyles within a genetic context, according to the 2025 Nature Communications analysis. Tobacco use compounds the risk further. According to a 2024 study in NEJM Evidence, approximately 18.8% of U.S. adults, or 47.7 million people, used at least one tobacco product, adding a significant additional burden to an already strained cardiovascular system.
Socioeconomic pressures are now part of the official clinical conversation. The 2026 guideline includes a recommendation for screening social factors that affect health – financial strain, food insecurity, and housing instability – specifically to identify patients at elevated CKM risk. Those factors don’t just affect lifestyle choices; they shape the biological environment in which metabolic dysfunction either takes root or doesn’t.
The First Clinical Guideline – and What It Changes
On June 9, 2026, the American Heart Association and the American College of Cardiology, along with two other leading medical organizations, issued the first-ever guideline aimed at preventing and managing CKM syndrome. The document was jointly developed with the American Diabetes Association and the American Society of Nephrology. For the first time, cardiologists, nephrologists, endocrinologists, and primary care physicians have a shared, standardized framework for identifying and treating this syndrome across disciplines.
The 2026 guideline introduces a comprehensive framework for the prevention, detection, evaluation, and management of CKM syndrome, and replaces, retires, and expands upon the 2013 guideline that addressed the management of overweight and obesity in adults. That’s a significant shift: a single-condition weight management guideline has been replaced by a multi-organ framework that treats obesity, high blood sugar, kidney disease, and cardiovascular risk as parts of the same problem.
Healthy lifestyle behaviors, medications including GLP-1-based therapies and SGLT2 inhibitors, and metabolic and bariatric surgery – when appropriate – are all recommended with the goal of preventing, managing, and potentially reversing CKM syndrome progression, according to the AHA’s announcement of the guideline. GLP-1-based therapies refer to drugs like semaglutide, which improve blood sugar regulation and support weight loss. SGLT2 inhibitors are a class of medication originally developed for diabetes that have since shown strong protective effects on the kidneys and heart.
The guideline also emphasizes the importance of healthy lifestyle behaviors and coordinated interdisciplinary care, encouraging patients to follow the AHA’s Life’s Essential 8 – a framework covering nutrition, physical activity, weight, blood pressure, blood glucose, cholesterol, sleep, and smoking cessation.
What to Do Now
CKM syndrome’s definition doesn’t require all three categories – heart disease, kidney disease, and metabolic dysfunction – to be present. Risk begins at Stage 1, which means even a single factor like prediabetes or excess weight already places someone on the spectrum. The goal of the staging system isn’t to alarm – it’s to trigger action earlier than the current medical system typically does.
Ask your doctor specifically about your kidney function, not just your blood pressure and blood sugar. Assessing the urine albumin-to-creatinine ratio and estimated glomerular filtration rate (eGFR) in Stage 1 patients leads to earlier detection of chronic kidney disease and improved patient outcomes. These tests aren’t automatically included in a standard annual blood panel. You may need to ask for them by name. eGFR is a measure of how well the kidneys are filtering the blood; albumin in the urine is one of the earliest signs that kidney function is under strain.
For adults with overweight or obesity, lifestyle modification is the first-line recommendation, with a goal of achieving at least 5% to 10% of baseline weight loss for CKM syndrome risk reduction, according to the 2026 guideline. That threshold, 5 to 10%, is achievable and clinically meaningful – it’s not a requirement to reach an ideal body weight before seeing measurable benefits. Losing that amount has documented effects on blood pressure, blood sugar, and kidney load.
Metabolic syndrome remains a valuable public health tool for identifying individuals at high risk of type 2 diabetes, cardiovascular diseases, chronic kidney disease, and early death – even before clinical disease manifests. That’s the case for knowing where you stand on the CKM spectrum: the earlier the intervention, the more of the progression you can intercept. The syndrome’s wide reach – covering nearly 9 in 10 adults – doesn’t mean that nearly 9 in 10 Americans are on a path to heart failure. It means that nearly 9 in 10 have at least one reason to pay closer attention than they probably do.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: U.S. States With The Highest Obesity Rates – and Why